The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®) on the surface of the eye and tear film (a film that coats the eye which is made up of oil and water).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
10
An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
Flaum Eye Institute at the University of Rochester
Rochester, New York, United States
Ocular Surface Temperature of Both Eyes
Lotemax® is an FDA-approved ophthalmic suspension for the treatment of steroid-responsive inflammatory conditions which include dry eye associated ocular surface inflammation. Lotemax® will serve as a vehicle to study the changes in the inflammatory mediators on the surface of the eye as well as collect the inflammatory mediators for laboratory analysis, utilizing Luminex instrumentation and standard ELISA assays.
Time frame: baseline, 30 minutes, week 1, week 2
Visual Quality
Using a Shack Hartmann wavefront sensor, measured root mean square of wavefront aberrations caused by dynamic tear film changes.
Time frame: baseline, 30 minutes, week 1, week 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.